Anti-MDL-1 antibodies
View Patent ↗Antibodies to human MDL-1 are provided, as well as uses thereof, e.g., in treatment of immune disorders, in particular, infectious diseases and sepsis.
1. A binding compound that binds to human MDL-1 comprising:
a) a light chain variable domain, or antigen binding fragment thereof, having a CDRL1 of SEQ ID NO: 43, a CDRL2 of SEQ ID NO: 51, and a CDRL3 of SEQ ID NO: 59; and
b) a heavy chain variable domain, or antigen binding fragment thereof, having a CDRH1 of SEQ ID NO: 19, a CDRH2 of SEQ ID NO: 27; and a CDRH3 of SEQ ID NO: 35.
2. The binding compound of claim 1 , wherein:
a) the light chain variable domain comprises the sequence of SEQ ID NO: 11; and
b) the heavy chain variable domain comprises the sequence of SEQ ID NO: 3.
3. The binding compound of claim 1 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, F(ab′) 2 , and a diabody.
4. The binding compound of claim 1 , wherein the binding compound is a monoclonal antibody.
5. The monoclonal antibody of claim 4 , wherein the monoclonal antibody comprises an antibody secreted by a hybridoma deposited with the ATCC as accession number PTA-8375.
6. The binding compound of claim 1 , wherein the binding compound is a humanized antibody comprising:
a) a variable light chain sequence of SEQ ID NO: 70; and
b) a variable heavy chain sequence of SEQ ID NO: 68.
7. The humanized antibody of claim 6 , further comprising a heavy chain constant region comprising a γ1 human heavy chain constant region.
8. The humanized antibody of claim 6 , further comprising a heavy chain constant region comprising a γ4 human heavy chain constant region.